Trial Profile
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2012
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 04 Oct 2011 Actual initiation date (December 2011) added as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Mar 2011 New trial record